f-star Biotechnology Research & Development Co.
This article was originally published in Start Up
Executive Summary
Vienna-based f-star Biotechnology's platform allows it to enhance the functionality of antibodies by introducing additional binding sites. F-star is also investigating antibody fragments and what it calls "compressed" antibodies, or protein scaffolds with key antibody characteristics tacked on, but much smaller in size. These, it claims, may be easier to produce than full-sized antibodies, with better tissue penetration and potentially better efficacy.